<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234127</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0244</org_study_id>
    <nct_id>NCT03234127</nct_id>
  </id_info>
  <brief_title>Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia</brief_title>
  <acronym>SAFIR</acronym>
  <official_title>Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of SAFIR is to identify the atherosclerotic genetic factors in these
      patients, which will identify new therapeutic targets for the treatment of CV and Familial
      Hypercholesterolemia diseases. In addition, SAFIR will allow the identification of new CV
      protection biomarkers, which will be useful tools for the development of a personalized
      medicine for the management of dyslipidemias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the SAFIR study is to perform non-invasive coronary vascular phenotyping of
      familial hypercholesterolemia (FH) families by performing a coronary calcium score and then
      to detect protective genetic factors in patients who do not have a significant atheroma
      despite a perturbed biological phenotype.

      The investigators will also conduct biochemical, lipidemic and metabolomic analyzes to
      identify a signature of biomarkers protective of cardiovascular risk in FH patients.

      The investigators will use the French FH register, which already includes 3889 patients, to
      identify these &quot;protected&quot; FH families within the main reference centers for the management
      of FH for inclusion and follow-up of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genes associated with the resistance to development of coronary atherosclerosis in subjects with heterozygous familial hypercholesterolemia</measure>
    <time_frame>3 years</time_frame>
    <description>Identification of functional genetic variants by a Whole Genome Sequencing (WGS) approach in case-control analysis (FH without and with advanced coronary atherosclerosis) and/or family analysis (protected and affected relatives)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of new biochemical, lipidemic, metabolomic and metagenomic biomarkers associated with cardiovascular protection in FH patients.</measure>
    <time_frame>3 years</time_frame>
    <description>Lipidic panel, phosphocalcic panel, Ceramides, Alipoproteins, Lp(a), lipidomic, LDL size, Phospholipids, TMAO, Carnitin, Cholin, microbiota, metabolomic, LDL Ox, Sterols, Isoprostan, oxidation, inflammation, cytokins, oxidative stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of arterial stiffness (reflected by the pulse wave velocity) with the development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of arterial stiffness measured by popmeter® (pulse wave velocity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of atherosclerosis of supra-aortic trunks (AST) with the development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of ASD through arterial Doppler ultrasonography (Intra-media thickness (IMT), degree of stenosis (ESCT), plaque)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of atherosclerosis of the lower limbs with the development of coronary atherosclerosis (PAD) in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of lower extremity involvement by arterial doppler ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between aortic valvular score and development of coronary atherosclerosis in FH patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between coronary calcium score and aortic valvular score in HF patients</measure>
    <time_frame>3 years</time_frame>
    <description>Measurement of coronary calcium score and aortic valvular score (optional) by a thoracic CT scan</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Atherosclerosis- resistance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FH Patient without atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FH patient with atheroclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the related population without familial hypercholesterolemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No FH patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole Genome Sequencing</intervention_name>
    <description>Whole Genome Sequencing Biomarkers analyses</description>
    <arm_group_label>Atherosclerosis- resistance</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>the related population without familial hypercholesterolemia</arm_group_label>
    <other_name>Biological analyzes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient agreeing to sign the consent of the study and the consent of biocollection

          -  Patient suffering from a familial hypercholesterolemia with a clinically-biologic
             score DLCN (Dutch Lipid Clinic Network, Annex 2)&gt; 8 and / or a causative mutation
             identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.

          -  Men ≥ 40 years of age; Female ≥ 50 years

          -  Patient affiliated to an existing social insurance

        The inclusion criteria to be met in the population with known coronary atheroma:

          -  Subject in secondary prevention of an atheromatous disease: coronary event or ischemic
             heart disease, irrespective of the result of the coronary calcium score; Ischemic
             stroke with proven carotid atheromatosis; revascularization (angioplasty, bypass
             surgery) or amputation in PAD

          -  Primary prevention topic CV with calcium score ≥ 400 Agatston units

        Inclusion criteria to be met in the population without cardiovascular risk:

        - No cardiovascular event (including MI, coronary revascularization, angina, stroke &amp;,
        Transiant ischemic attack of atheromatous origin, PAD) with: For women between 50 and 65
        years, a nil calcium score * For women between 65 and 75 years of age, a calcium score** ≤
        10 Agatston units For women over 75 years of age, a calcium score** ≤ 20 Agatston units For
        men between 40 and 55 years of age, a nil calcium score* for men For men between 55 and 70
        years of age, a calcium score** ≤ 10 Agatston units For men over 70 years of age, a calcium
        score** ≤ 20 Agatston units

          -  40 year old men and 50 year old women: less than 6 months old

          -  41 year old men and 51 year old women: under 1 year old

          -  42 year old men and 52 year old women: under 2 years old

          -  43 year old men and 53 year old women: under 3 years old

          -  44 year old men and 54 year old women: under 4 years old

               -  Less than 5 years

        Inclusion criteria to be met in the related population with familial hypercholesterolemia :

          -  Patient agreeing to sign the consent of the study and the consent of biocollection

          -  Patient suffering from a familial hypercholesterolemia with a clinically-biologic
             score DLCN (Dutch Lipid Clinic Network, Annex 2)&gt; 8 and / or a causative mutation
             identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.

          -  Men or Female ≥ 30 years

          -  Patient affiliated to an existing social insurance

        Inclusion criteria to be met in the related population without familial
        hypercholesterolemia :

          -  Patient agreeing to sign the consent of the study and the consent of biocollection

          -  Patient not suffering from a familial hypercholesterolemia related to one of the
             members of the population suffering from familial hypercholesterolemia without
             cardiovascular risk

          -  Men or Female ≥ 18 years

          -  Patient affiliated to an existing social insurance

        Exclusion Criteria:

          -  Subject suffering from active cancer or progressive neoplasia

          -  Subject treated with recent corticosteroid therapy

          -  Subjects with unsubstituted or poorly controlled hypothyroidism (TSH&gt; normal)

          -  Subject receiving immunosuppressive or anti-cancer treatment

          -  Subject refusing to participate

          -  Subjects under tutelage, curatorship or a safeguard of justice or without social
             insurance

        The exclusion criterion for all populations except the related population without familial
        hypercholesterolemia:

        - Subject with no &quot;definite&quot; familial hypercholesterolemia according to the DLCN score
        (≤8), after auction. The purpose of the auction will be to rule on the causal nature of an
        identified mutation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthieu PICHELIN</last_name>
    <phone>02 53 48 27 06</phone>
    <email>matthieu.pichelin@univ-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <phone>02.53.48.27.07</phone>
    <email>bertrand.cariou@univ-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Le Bocage Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>29079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves COTTIN, Pr</last_name>
      <phone>03.80.28.12.55</phone>
      <email>yves.cottin@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Yves COTTIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile YELNIK</last_name>
      <phone>0320445479</phone>
      <email>cecile.yelnik@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile YELNIK</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louis Pradel Cardiovascular Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MOULIN, Pr</last_name>
      <phone>04.72.68.13.04</phone>
      <email>philippe.moulin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe MOULIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Conception Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie BELIARD, Dr</last_name>
      <phone>04.91.38.36.50</phone>
      <email>Sophie.BELIARD@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie BELIARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <phone>02.53.48.27.07</phone>
      <email>bertrand.cariou@univ-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck BOCCARA, Dr</last_name>
      <phone>01.49.28.24.49</phone>
      <email>franck.boccara@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Franck BOCCARA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric BRUCKERT, Pr</last_name>
      <phone>01.42.17.57.85</phone>
      <email>eric.bruckert@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Eric BRUCKERT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François PAILLARD, Dr</last_name>
      <phone>02.99.28.25.40</phone>
      <email>francois.paillard@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>François PAILLARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean FERRIERES, Pr</last_name>
      <phone>05.61.32.33.39</phone>
      <email>ferrieres.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean FERRIERES, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

